PDCD1 and neoplasm: Notably, even tumors with a high tumor mutational burden (TMB) or microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR) phenotype – features generally associated with heightened immunogenicity – can manifest primary or acquired resistance to PD-1 (92).